Slide 1: 2025 Full-Year & Business Update
2025 Full-Year & Business Update Conference Call 1 March 24, 2026 • 6:00 p.m. CET / 1:00 p.m. ET
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: On Today's Call
On Today’s Call Click to edit Master title style LUCIE LARGUIER VP, Chief Financial Officer Transgene investorrelations@transgene.fr Dr ALESSANDRO RIVA, MD Chairman and Chief Executive Officer Transgene 3
Slide 4: Progressing INTVs from Platform Towards Pivotal Trial
Progressing INTVs from Platform Towards Pivotal Trial Click to edit Master title style Indication Discovery/Research Phase 1 Phase 2 Phase 3 INDIVIDUALIZED NEOANTIGEN THERAPEUTIC VACCINES (INTVs) Head and Neck Cancer Randomized Phase 1/2 (HNSCC) (adjuvant) TG4050 Additional indication Phase 1 (adjuv
Slide 5: TG4050 – Durable Immunogenicity Confirms Mechanism of Action
TG4050 – Durable Immunogenicity Confirms Mechanism of Action Clinical Click and translational to edit Master title style evidence positions TG4050 as a leading INTV candidate for adjuvant treatment of operable cancers ASCO – June. 2025 SITC – Nov. 2025 medRxiv Publication — Jan. 2026 ✓ Neoantigen-sp
Slide 6: TG4050 – Phase 2 Part of the Trial on Track
TG4050 – Phase 2 Part of the Trial on Track Expansion to Second Click to edit Master title style Indication Ph. 2 of the Ph.1/2 study New Ph. 1 trial Head & Neck Cancer (HNSCC*) Second Indication*** ➢ Randomization nearly completed ➢ 2026: Start-up activities underway for Ph. 1 ➢ First Ph. 2 immunog
Slide 7: BT-001 – Updated Phase 1 Data Support Further Clinical Development
BT-001 – Updated Phase 1 Data Support Further Clinical Development Click to edit Master title style Phase 1 data — intratumorally administered oncolytic virus ✓ Updated Ph. 1 data in combination with KEYTRUDA® (pembrolizumab) presented at ESMO Annual Meeting 2025*; ✓ Confirmed positive local, abscop
Slide 8: Finance & Outlook
Finance & Outlook E 1010101 @ vor000 oomoc 0010) no101 e 100 1010 @ 010 jis oonen @ oO ~—or01010 ee os @ vx @ e 1 00100 om00i00 = oonon oo ). fe 0 1 o® Petes emenim tiooon1099 1100 @ CGTAcTGGc @ 1.09 @ avoarore500 onion jonoi0@ ioom @ 00101 =m @ 01 mec cor0010% 1000101 jono) @ owo o ot yon 1 10 no!
Slide 9: Business Funded Until Early 2028
Business Funded Until Early 2028 Enables the acceleration Click to edit Master title style of the development of Transgene’s INTV myvac® programs €105M fundraising in Dec. 2025, runway extended to early 2028 Cash, cash equivalents and other €111.9M €111.9M financial assets year-end 2025 Debt convert
Slide 10: Investment Highlights – Key Upcoming Milestones
Investment Highlights – Key Upcoming Milestones TG4050 Click to editand Master title style platform Part 1 of the Ph.1/2 trial Ph. 2 part of the Ph. 1/2 trial in HNSCC in HNSCC New Phase 1 — Second Indication* ➢ Q2/Q3 2026: 3-year follow-up ➢ Randomization nearly completed ➢ 2026: Ph. 1 trial in a s
Slide 11: Questions & Answers
ge [ a ao cocceeseceSeges -eo0e ee p01 20 1001010 CGTACTGGC « Questions & Answers “ transgene
Slide 12: Transgene is uniquely positioned to deliver on individualized neoantigen therapeutic vaccines
Transgene is uniquely positioned to deliver on the promise of individualized neoantigen therapeutic vaccines 12
Slide 13: Contact
CONTACT Alessandro Riva Chairman & CEO Lucie Larguier CFO investorrelations@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 00 | www.transgene.com 13
Slide 14: Appendices
Appendices “ transgene
Slide 15: myvac® Potential to Further Reduce the Risk of Relapse in Early-Stage Solid Tumors
myvac® has the Potential to Further Reduce the Risk of Relapse in Early-Stage Solid Tumors Click to edit Master title style ICI-based perioperative treatment regimen By further preventing relapse, the myvac® platform are improving patient outcome could become a multi-billion opportunity but the risk
Slide 16: TG4050 HNSCC Phase 1 Data – 100% DFS 2 Years after Treatment Initiation
TG4050 | HNSCC Phase 1 Data – 100% DFS 2 Years after Treatment Initiation Clinical Click to edit Proof of style Master title Principle in Adjuvant Setting Good safety profile 2-year disease-free survival (DFS) (see appendix) Median follow-up of 30 months 100% All 16 treated patients remained disease
Slide 17: TG4050 HNSCC Phase 1 Data – Patient Population Balanced for Major Prognostic Factors
TG4050 | HNSCC Phase 1 Data – Patient Population Balanced for Major Prognostic Factors Click to edit Master title style Arm A Arm B Arm A Arm B Patient Characteristics (N=17*) (N=16) Pathological Risk Factors (N=17*) (N=16) TG4050 single agent Watchful waiting TG4050 single agent Watchful waiting Ma
Slide 18: Adjuvant HNSCC, Still a Significant Medical Need
Adjuvant HNSCC, Still a Significant Medical Need Click to edit Master title style Despite ICI-containing adjuvant treatment emerge as new SOC for 35% OF PATIENTS RELAPSE operable squamous H&N cancer patients, high medical need remains: WITHIN 2 YEARS KEYNOTE 689 NivoPostOp Medical need despite the a